Lantern Pharma

LTRN

Market cap $28.1M

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for mid-May 2026 to seek feedback on proposed protocol amendments to its ongoing Phase 2 HARMONIC™ clinical trial evaluating LP-300. The amendments are grounded in emerging clinical data demonstrating a meaningful and consistent progression-free survival signal in patients with EGFR Exon 21 L858R-.

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN) (“Lantern” or the “Company”), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai — the world's first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, biomedical research, molecular design and clinical trial development — is now commercially live and actively onboarding subscribers. Subscriptions are available immediately at withzeta.ai, spanning intr.

Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript

DALLAS--(BUSINESS WIRE)--withZeta.ai is redefining how rare cancer research, discovery, drug development, and clinical trial design gets done.

Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript

DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates.

DALLAS--(BUSINESS WIRE)--Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report.

DALLAS--(BUSINESS WIRE)--Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001.

DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET.

DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026.